Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
2.960
-0.040 (-1.33%)
At close: Nov 20, 2024, 4:00 PM
2.900
-0.060 (-2.03%)
Pre-market: Nov 21, 2024, 5:48 AM EST

Galmed Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
3.763.924.665.664.134.2
Upgrade
Research & Development
3.033.571327.2226.0818.18
Upgrade
Operating Expenses
6.797.4917.6532.8830.2122.38
Upgrade
Operating Income
-6.79-7.49-17.65-32.88-30.21-22.38
Upgrade
Interest & Investment Income
0.380.380.30.561.191.95
Upgrade
Currency Exchange Gain (Loss)
-0.04-0.040.04-0.03-0.12-0.11
Upgrade
Other Non Operating Income (Expenses)
-0.13-0.01-0.02-0.04-0.03-0.03
Upgrade
EBT Excluding Unusual Items
-6.58-7.16-17.34-32.39-29.17-20.57
Upgrade
Gain (Loss) on Sale of Investments
0.250.25-0.53-0.080.40.11
Upgrade
Pretax Income
-6.32-6.91-17.87-32.47-28.77-20.46
Upgrade
Net Income
-6.32-6.91-17.87-32.47-28.77-20.46
Upgrade
Net Income to Common
-6.32-6.91-17.87-32.47-28.77-20.46
Upgrade
Shares Outstanding (Basic)
100000
Upgrade
Shares Outstanding (Diluted)
100000
Upgrade
Shares Change (YoY)
136.81%65.23%2.22%15.59%0.79%16.41%
Upgrade
EPS (Basic)
-11.32-29.95-127.90-237.59-243.35-174.43
Upgrade
EPS (Diluted)
-13.19-30.00-127.90-237.60-243.35-174.43
Upgrade
Free Cash Flow
-4.81-6.14-18.51-32.9-26.33-14.95
Upgrade
Free Cash Flow Per Share
-8.60-26.59-132.48-240.78-222.72-127.44
Upgrade
EBITDA
-6.7-7.46-17.62-32.84-30.17-22.34
Upgrade
D&A For EBITDA
0.090.030.040.040.040.04
Upgrade
EBIT
-6.79-7.49-17.65-32.88-30.21-22.38
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.